<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909892</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-PLH-201</org_study_id>
    <nct_id>NCT04909892</nct_id>
  </id_info>
  <brief_title>Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 &quot;Long Haul&quot; Pulmonary Compromise</brief_title>
  <official_title>A Phase 2a Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 &quot;Long Haul&quot; Pulmonary Compromise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b study to assess the safety and efficacy of COVI-MSC in treating post&#xD;
      COVID-19 &quot;long haulers&quot; with pulmonary compromise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b multicenter study to assess the safety and efficacy of COVI-MSC in&#xD;
      treating post COVID-19 &quot;long haulers&quot; with pulmonary compromise.&#xD;
&#xD;
      COVI-MSC will be administered intravenously on Day 0, Day 2, and Day 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Replaced by a different protocol.&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-Minute Walk Distance (6MWD) at Day 60</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>Change in 6MWD at Day 60</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6MWD at Day 30</measure>
    <time_frame>Baseline to Day 30</time_frame>
    <description>Change in 6MWD at Day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function Tests (PFTs)</measure>
    <time_frame>Baseline to Day 30 and Day 60</time_frame>
    <description>Change in PFTs at Days 30 and 60, as assessed using Forced Vital Capacity, Forced Expiratory Volume, Total Lung Capacity, and diffusing capacity for carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygenation</measure>
    <time_frame>Baseline to Day 30 and Day 60</time_frame>
    <description>Change in oxygenation at Days 30 and 60, as measured using SpO2/FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarker levels</measure>
    <time_frame>Baseline through Day 30</time_frame>
    <description>Change in biomarker levels: plasma lipocalcin-2, matrix metalloproteinase-7, hepatocyte growth factor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVI-MSC 1 vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous infusions of COVI-MSC (one vial, ~18.5 million cells) on Day 0, Day 2, and Day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVI-MSC 2 vials</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous infusions of COVI-MSC (two vials, ~37 million cells) on Day 0, Day 2, and Day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVI-MSC</intervention_name>
    <description>COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells</description>
    <arm_group_label>COVI-MSC 1 vial</arm_group_label>
    <arm_group_label>COVI-MSC 2 vials</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has had prior laboratory-confirmed SARS-CoV-2 infection as determined by an approved&#xD;
             polymerase chain reaction (PCR) or an approved antigen test of any specimen&#xD;
&#xD;
          -  Has had a recent (within a week) negative SARS-CoV-2 test (an approved PCR or antigen&#xD;
             test)&#xD;
&#xD;
          -  Has had at least moderate or severe post-COVID-19 pulmonary symptoms for at least 3&#xD;
             months which have resulted in reduced physical functioning compared to pre-COVID-19&#xD;
             status&#xD;
&#xD;
          -  Willing to follow contraception guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically improving pulmonary status over the month prior to screening&#xD;
&#xD;
          -  Undergone a previous stem cell infusion unrelated to this trial&#xD;
&#xD;
          -  Pregnant or breast feeding or planning for either during the study&#xD;
&#xD;
          -  Suspected uncontrolled active bacterial, fungal, viral, or other infection&#xD;
&#xD;
          -  History of a splenectomy, lung transplant or lung lobectomy&#xD;
&#xD;
          -  Concurrent participation in another clinical trial involving therapeutic interventions&#xD;
             (observational study participation is acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid-19</keyword>
  <keyword>long haul</keyword>
  <keyword>post-acute covid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

